INCATE

The new World Health Organization Global AMR Surveillance Report 2025 reveals that 1 in 6 bacterial infections worldwide in 2023 were resistant to antibiotics, with resistance increasing in over 40% of pathogen–antibiotic combinations since 2018. Gram-negative bacteria like E. coli and K. pneumoniae are becoming resistant to even last-resort antibiotics, especially in regions least equipped to respond. At INCATE, this report reinforces what drives our mission every day, AMR innovation is not optional: it’s urgent. We support innovators in the development of new therapies, and interventions that help reduce the prevalence and impact of AMR — because stronger surveillance must be matched by stronger innovation. The message is clear: the world needs new antimicrobials, and it needs them soon. At INCATE, we’re working every day to make that possible. Read the WHO report ➡️ https://lnkd.in/ezYXeMdM

Preparing for your next fundraising round? You won’t want to miss this session, packed with hands-on insights on how to make your company truly investor-ready, from the perspective of a practicing Attorney at Law. Peak Spirit Academy, together with Viopas Venture Consulting GmbH, are holding a webinar on: “Get Fundraising-Ready: Lawyers’ Insights on Due Diligence”, with Dr. Umberto Milano, Partner at Kellerhals Carrard. 🗓 October 30, 2025 🕓 4.00 – 5.00pm CET 📍 Online Register here ➡️ https://lnkd.in/ewyBFeq6 Make sure your next funding round doesn’t just start strong, but ends with a signed term sheet!

Don’t miss the AMR Conference 2026! The journey is warming up: - Poster Abstract Call is open - Startup Pitch Event coming soon - More updates on the way Still unsure if you should join? Check out the highlights from the 2025 edition and see why this is the place to be in AMR innovation ➡️ https://lnkd.in/eaiBKFrb 📍 Save the date: Basel, March 3-4 2026. See you there!

Have you signed up to our newsletter yet? Get expert insights, breaking news, and key updates delivered straight to your inbox. Sign up for our newsletter now ➡️ https://lnkd.in/dxq4JtMt Don't fall behind!

New insights on pneumococcal vaccination in older adults! A recent randomized trial asked a simple but important question: Should PCV13 and PPSV23 vaccines be given together or one after the other to boost immunity the most? What they did: Vaccine-naïve adults ≥60 years were studied using an innovative readout—antigen-specific memory B cells—to track immune responses. Key takeaways: - Simultaneous vaccination: safe and effective. - Sequential vaccination (PCV13 → PPSV23 after 6 months): strongest long-term memory B cell and antibody responses. - Safety: all strategies well tolerated, but sequential wins for lasting protection. Bottom line: Giving both vaccines at the same time works—but spacing them out delivers the most durable immunity, supporting current STIKO guidance. Read it here ➡️ https://lnkd.in/e8Wf3xP3 Christina Bahrs | Nico Andreas | Thomas Lehmann | Sabine Baumgart | Charlotte Sværke Jørgensen | Oliwia Makarewicz | Daniela Röll | Anne Moeser | PD Dr. med. habil. Stefan Hagel, M.Sc. | Carsten Watzl | Christian Bogdan | Thomas Kamradt | Mathias W. Pletz, MD, Prof. Dr. med. 

The Poster Abstract Call for the AMR Conference 2026 is now officially OPEN! We invite scientists to showcase their work on cutting-edge AMR research. This is your chance to share your science, connect with peers, and shape the future of antimicrobial innovation. Topics include: - Basic understanding of bacterial infections - Novel antibacterial therapies - Antibiotic mechanism of action studies - Preclinical development & enabling technologies - Novel diagnostics - AI-driven approaches - Clinical trial design Why should you apply? - Free poster presentation (no fee!) - Presenting author gets a complimentary full conference ticket - First prize of up to €1,000 📅 Deadline: January 7, 2026 All details & submission ➡️ https://lnkd.in/ehhEVyTG We can’t wait to see your posters and celebrate the most exciting work in AMR!

 Fighting antimicrobial resistance takes more than innovation: it takes knowledge and collaboration. That’s why at INCATE we recommend checking out REVIVE from Global Antibiotic R&D Partnership (GARDP) — a global, free knowledge hub for antimicrobial R&D. Thank you for your great work!

The Secret Social Lives of Bacteria Did you know our bodies are home to trillions of bacteria — and, just like us, they have complex social lives? Which bacteria are loners, who thrives in a crowd, and who cheats or backstabs? Could there really be a microbial version of The Godfather? In this episode, Sally Le Page explores these bacterial dramas: how cooperation, selfishness, and backstabbing can influence health, disease, and the environment. How can understanding these social dynamics help scientists develop new medicines or innovative ways to clean up our world? Tune in to discover the fascinating, sometimes surprising, social life of microbes! ➡️ https://lnkd.in/eZRdEGCF

The German Center for Infection Research (DZIF) is supporting spin-offs in translational infection research with tailored mentoring and up to €500,000 in funding. - Focus: Preventive & therapeutic anti-infective innovations - Deadline: November 30, 2025 Requirements for application - At least one applicant must be a principal investigator at the DZIF - Availability of a commercial asset and business idea, e.g., a patent (application), relevant know-how or a compelling service concept - Availability of a team of co-founders, whereby two individuals will be expected to (partly) transfer to the company after successful incorporation - Written confirmation from the technology transfer office of the member institution to license or transfer the Intellectual Property or asset Turn your lab idea into a company with expert guidance from DZIF! All info here ➡️ https://lnkd.in/e8yAVF6d

AI: the future or the present in antibiotics research? Artificial intelligence, particularly machine learning, is already revolutionizing antibiotic discovery. Researchers are leveraging AI to identify new compounds that combat drug-resistant bacteria, a critical step in addressing AMR. For instance, AI has been crucial in discovering novel antibiotics capable of targeting resistant strains like MRSA and Acinetobacter baumannii. These advancements are not just theoretical; they are actively shaping the development of next-generation therapeutics. As we continue to confront the growing threat of AMR, integrating AI into our research and development processes is no longer optional — it's essential. Read more ➡️ https://lnkd.in/eezRVEEV